← Leaderboards
Inga-Marie Schaefer
Brigham And Women'S Hospital
$1,503,050
Attributed
$1,503,050
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $361.1K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,503,050 · 1
By mechanism
K08$1,503,050 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Keith L Ligon$15,402,631
- Mario Luca Suva$9,318,589
- Joann Elisabeth Manson$50,755,529
- Charles S Fuchs$37,354,862
- Natasha Y Frank$4,964,719
Others in their field
Other Emerging Leaders on “Disease Progression”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$111,936,677
- Klaus Romero · Critical Path Institute$90,404,592
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$45,424,821
- Ryan Cirz · Revagenix, Inc.$40,209,479
Research focus
Disease ProgressionAdvanced DiseaseBehaviorAdvisory CommitteesBiologicalBiologyCancer ModelCareerCareer DevelopmentBenignCell CycleCell GrowthCell SurvivalChromosome DeletionClinical PracticeClinical TrialsCollaborationsCombined Modality TherapyCrispr ScreenDependenceDiagnosisCdk4 GeneDisciplineDisease Resistance
Grant awards (6)
Targeting cell cycle dysregulation in GIST$285,490
K08 · FY2023 · CA · contact PI
Targeting cell cycle dysregulation in GIST$75,600
K08 · FY2023 · CA · contact PI
Targeting cell cycle dysregulation in GIST$285,490
K08 · FY2022 · CA · contact PI
Targeting cell cycle dysregulation in GIST$285,490
K08 · FY2021 · CA · contact PI
Targeting cell cycle dysregulation in GIST$285,490
K08 · FY2020 · CA · contact PI
Targeting cell cycle dysregulation in GIST$285,490
K08 · FY2019 · CA · contact PI